Skip to main content
Neurology logoLink to Neurology
. 2020 Oct 6;95(14):661. doi: 10.1212/WNL.0000000000008927

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

PMCID: PMC8105950  PMID: 32938789

In the article “Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients” by Plavina et al.,1 there is an error in the “Monocyte/VCAM-1 binding” key of figure 3. “Natalizumab continued” should have been represented by a green line and gray square; “Natalizumab interrupted” should have been represented by a red line and black circle. The editorial office regrets the errors.

Figure 3. Functional activity of CD3+ T cells, CD19+ B cells, and monocytes from RESTORE patients.

Figure 3

Reference

  • 1.Plavina T, Muralidharan KK, Kuesters G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology 2017;89:1584–1593. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neurology are provided here courtesy of American Academy of Neurology

RESOURCES